KIO-104 not checked

Kiora Pharmaceuticals, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“KIO-104 is an ophthalmic formulation for IVT injection of the active pharmaceutical ingredient (API) KIO-100, a novel, non-steroidal, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).”In the company’s words, NCT06825702 on ClinicalTrials.gov
Tested for
Macular Edema
Main trialPhase 2
“This is a multi-center, open label study to assess the safety, tolerability, and efficacy of KIO-104 administered by IVT injection to the study eye of eligible participants with macular edema.”In the company’s words, NCT06825702 on ClinicalTrials.gov

Other drugs for Macular Edema

All 6 drugs for Macular Edema

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Recruiting Nov 2026 Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow KIO-104

Following is part of Solo: you see every change to KIO-104 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in